Selecta Bioscience Inc. published preclinical data this week suggesting its immune tolerance therapy SVP-Rapamycin (SEL-110), which is in a phase I trial to prevent the formation of antidrug ...
To treat osteoarthritis, a chronic joint condition, researchers at the Indian Institute of Science (IISc), have developed a micro-particle formulation that allows sustained release of drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback